Suzuki et al. [41] examined by ELISA the presence of serum AAbs to cyclin B1 in 120 patients (7 with breast carcinoma, 17 with pancreatic cancer, 27 with colon cancer, and 69 with lung cancer) and found that the highest proportion of patients strongly positive (absorbance ≥ 1) for AABs to cyclin B1 was in the breast carcinoma group (3/7, 42.8%). Here, CCNB1 is linked to breast carcinoma.